Niranjan Kanesa-thasan
Chief Tech/Sci/R&D Officer bei ICOSAVAX, INC.
Profil
Niranjan Kanesa-thasan is the founder of Kanesa LLC, which was founded in 2017.
He is currently the Chief Medical Officer at Icosavax, Inc. since 2018.
He was previously the Chief Medical Officer-North America & VP at Novartis Vaccines & Diagnostics, Inc. from 2007 to 2015, and the Vice President-Clinical Research & Development at GSK Vaccines from 2015 to 2017.
Dr. Kanesa-thasan has an undergraduate degree from The Johns Hopkins University, a graduate degree from Uniformed Services University of the Health Sciences, and a doctorate degree from The Johns Hopkins University School of Medicine.
Aktive Positionen von Niranjan Kanesa-thasan
Unternehmen | Position | Beginn |
---|---|---|
ICOSAVAX, INC. | Chief Tech/Sci/R&D Officer | 01.09.2018 |
Ehemalige bekannte Positionen von Niranjan Kanesa-thasan
Unternehmen | Position | Ende |
---|---|---|
Kanesa LLC | Founder | 01.08.2019 |
GSK Vaccines | Chief Tech/Sci/R&D Officer | 01.08.2017 |
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01.01.2015 |
Ausbildung von Niranjan Kanesa-thasan
The Johns Hopkins University | Undergraduate Degree |
Uniformed Services University of the Health Sciences | Graduate Degree |
The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
Icosavax, Inc.
Icosavax, Inc. Pharmaceuticals: MajorHealth Technology Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA. | Health Technology |
GSK Vaccines | |
Kanesa LLC |